Cargando…

The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans

Intranasal delivery provides a practical, noninvasive method of bypassing the blood-brain barrier (BBB) in order to deliver therapeutic agents to the brain. This method allows drugs that do not cross the BBB to be delivered to the central nervous system in a few minutes. With this technology, it wil...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Rodríguez, Julio Cesar, Sosa Teste, Iliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: TheScientificWorldJOURNAL 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823095/
https://www.ncbi.nlm.nih.gov/pubmed/19768354
http://dx.doi.org/10.1100/tsw.2009.103
_version_ 1783301813615722496
author García-Rodríguez, Julio Cesar
Sosa Teste, Iliana
author_facet García-Rodríguez, Julio Cesar
Sosa Teste, Iliana
author_sort García-Rodríguez, Julio Cesar
collection PubMed
description Intranasal delivery provides a practical, noninvasive method of bypassing the blood-brain barrier (BBB) in order to deliver therapeutic agents to the brain. This method allows drugs that do not cross the BBB to be delivered to the central nervous system in a few minutes. With this technology, it will be possible to eliminate systemic administration and its potential side effects. Using the intranasal delivery system, researchers have demonstrated neuroprotective effects in different animal models of stroke using erythropoietin (EPO) as a neuroprotector or other different types of EPO without erythropoiesis-stimulating activity. These new molecules retain their ability to protect neural tissue against injury and they include Asialoerythropoietin (asialoEPO) carbamylated EPO (CEPO), and rHu-EPO with low sialic acid content (Neuro-EPO). Contrary to the other EPO variants, Neuro-EPO is not chemically modified, making it biologically similar to endogenous EPO, with the advantage of less adverse reactions when this molecule is applied chronically. This constitutes a potential benefit of Neuro-EPO over other variants of EPO for the chronic treatment of neurodegenerative illnesses. Nasal administration of EPO is a potential, novel, neurotherapeutic approach. However, it will be necessary to initiate clinical trials in stroke patients using intranasal delivery in order to obtain the clinical evidence of its neuroprotectant capacity in the treatment of patients with acute stroke and other neurodegenerative disorders. This new therapeutic approach could revolutionize the treatment of neurodegenerative disorders in the 21 century.
format Online
Article
Text
id pubmed-5823095
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher TheScientificWorldJOURNAL
record_format MEDLINE/PubMed
spelling pubmed-58230952018-03-14 The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans García-Rodríguez, Julio Cesar Sosa Teste, Iliana ScientificWorldJournal Review Article Intranasal delivery provides a practical, noninvasive method of bypassing the blood-brain barrier (BBB) in order to deliver therapeutic agents to the brain. This method allows drugs that do not cross the BBB to be delivered to the central nervous system in a few minutes. With this technology, it will be possible to eliminate systemic administration and its potential side effects. Using the intranasal delivery system, researchers have demonstrated neuroprotective effects in different animal models of stroke using erythropoietin (EPO) as a neuroprotector or other different types of EPO without erythropoiesis-stimulating activity. These new molecules retain their ability to protect neural tissue against injury and they include Asialoerythropoietin (asialoEPO) carbamylated EPO (CEPO), and rHu-EPO with low sialic acid content (Neuro-EPO). Contrary to the other EPO variants, Neuro-EPO is not chemically modified, making it biologically similar to endogenous EPO, with the advantage of less adverse reactions when this molecule is applied chronically. This constitutes a potential benefit of Neuro-EPO over other variants of EPO for the chronic treatment of neurodegenerative illnesses. Nasal administration of EPO is a potential, novel, neurotherapeutic approach. However, it will be necessary to initiate clinical trials in stroke patients using intranasal delivery in order to obtain the clinical evidence of its neuroprotectant capacity in the treatment of patients with acute stroke and other neurodegenerative disorders. This new therapeutic approach could revolutionize the treatment of neurodegenerative disorders in the 21 century. TheScientificWorldJOURNAL 2009-09-15 /pmc/articles/PMC5823095/ /pubmed/19768354 http://dx.doi.org/10.1100/tsw.2009.103 Text en Copyright © 2009 Julio Cesar Garcia-Rodriguez and Iliana Sosa-Teste. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
García-Rodríguez, Julio Cesar
Sosa Teste, Iliana
The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans
title The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans
title_full The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans
title_fullStr The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans
title_full_unstemmed The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans
title_short The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans
title_sort nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823095/
https://www.ncbi.nlm.nih.gov/pubmed/19768354
http://dx.doi.org/10.1100/tsw.2009.103
work_keys_str_mv AT garciarodriguezjuliocesar thenasalrouteasapotentialpathwayfordeliveryoferythropoietininthetreatmentofacuteischemicstrokeinhumans
AT sosatesteiliana thenasalrouteasapotentialpathwayfordeliveryoferythropoietininthetreatmentofacuteischemicstrokeinhumans
AT garciarodriguezjuliocesar nasalrouteasapotentialpathwayfordeliveryoferythropoietininthetreatmentofacuteischemicstrokeinhumans
AT sosatesteiliana nasalrouteasapotentialpathwayfordeliveryoferythropoietininthetreatmentofacuteischemicstrokeinhumans